Most infectious diseases are caused by pathogenic infiltrations from the mucosal tract.
Therefore, vaccines delivered to the mucosal tissues can mimic natural infections and …

The management of RRP is ever evolving. Despite several new therapies discussed in this
study, it is still a disease with the potential for high morbidity. As the focus of therapy shifts …

Background Effective vaccination against human papillomavirus (HPV) represents an
opportunity to control cervical cancer. Peptide-based vaccines targeting HPV E6 and/or E7 …

Current therapeutic approaches to treatment of patients with bulky cervical cancer are based
on conventional in situ ablative modalities including cisplatin-based chemotherapy and …

Persistent infection by high risk genotypes of human papillomavirus (HPV) is the cause of
cervical cancer, which remains one of the most common cancers among women worldwide …

The mechanism for pathogenesis of human papillomavirus (HPV) in the cervix has been
investigated intensively. However, detailed differences in the distribution and function of …

The tumor-suppressing effects of SipB160/HPV16 E7 fusion protein, derived from human
papillomavirus, and expressed in Salmonella enterica serovar typhimurium, were evaluated …

Cervical cancer is the leading cause of cancer-related deaths among women worldwide.
Current prophylactic vaccines based on HPV (Human papillomavirus) late gene protein, L1 …

Despite recent advances in the immune mechanisms of cervical cancer (CC), the relapse
still remains an actual issue and recognition of new predictive biomarkers is essential. Aim …

Cervical cancer is an urgent problem due to its high morbidity, its growth tendency in women
of reproductive age, and late presentation. As a result of insufficiently effective surgical …